Effects of titrated arginine vasopressin on hemodynamic variables and oxygen transport in healthy and endotoxemic sheep

Crit Care Med. 2003 May;31(5):1502-8. doi: 10.1097/01.CCM.0000063042.15272.84.

Abstract

Objective: To determine the effects of titrated arginine vasopressin (AVP) alone or in combination with norepinephrine (NE) on hemodynamics and oxygen transport in healthy and endotoxemic sheep.

Design: Prospective controlled trial.

Setting: University research laboratory.

Subjects: Six adult ewes.

Interventions: Healthy sheep received AVP as a titrated infusion, initiated with 0.6 units/hr and increased by 0.6 units/hr every 15 mins, either until mean arterial pressure was increased by 20 mm Hg vs. baseline or a maximum of 3.6 units/hr was administered. After 90 mins, AVP infusion was continued with the investigated dosage, and NE (0.2 microg x kg(-1) x min(-1)) was also infused for 90 mins. After a 24-hr period of recovery, endotoxemia was induced and maintained (Salmonella typhosa endotoxin, 10 ng x kg(-1) x min(-1)) in the same sheep for the next 19 hrs. After 16 hrs of endotoxemia, AVP and NE were administered as described previously.

Measurements and main results: Hemodynamics were obtained at baseline, every 15 mins during the titration period, and 60 and 90 mins after additional NE infusion. Variables of oxygen transport were calculated before and after the titration period. In healthy and endotoxemic sheep, AVP reduced heart rate and cardiac index (p <.001) and compromised oxygen delivery (p <.001) and oxygen consumption (healthy sheep, p =.003; endotoxemic sheep, p <.001). Vasopressin infusion did not alter mean pulmonary arterial pressure but increased pulmonary vascular resistance index in both groups (p <.001). Additional infusion of NE further augmented mean arterial pressure and increased cardiac index during endotoxemia (p <.001). This was accompanied by an increase in oxygen delivery and consumption (p <.05 each).

Conclusions: During ovine endotoxemia, AVP decreased cardiac index, compromised oxygen delivery, and increased pulmonary vascular resistance index. These side effects may limit its use as a sole vasopressor during sepsis. Potentially, a simultaneous infusion of AVP and NE could represent a useful therapeutic option.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Arginine Vasopressin / administration & dosage*
  • Arginine Vasopressin / pharmacology
  • Blood Pressure / drug effects
  • Cardiac Output / drug effects
  • Disease Models, Animal*
  • Drug Administration Schedule
  • Drug Evaluation, Preclinical
  • Drug Monitoring
  • Drug Therapy, Combination
  • Endotoxemia / drug therapy*
  • Endotoxemia / metabolism*
  • Female
  • Heart Rate / drug effects
  • Hemodynamics / drug effects*
  • Infusions, Intravenous
  • Norepinephrine / pharmacology
  • Norepinephrine / therapeutic use
  • Oxygen Consumption / drug effects*
  • Prospective Studies
  • Pulmonary Wedge Pressure / drug effects
  • Respiratory Transport / drug effects*
  • Sheep
  • Typhoid Fever / drug therapy*
  • Typhoid Fever / metabolism*
  • Vascular Resistance / drug effects
  • Vasoconstrictor Agents / administration & dosage*
  • Vasoconstrictor Agents / pharmacology

Substances

  • Vasoconstrictor Agents
  • Arginine Vasopressin
  • Norepinephrine